FTC expands pharma scrutiny to early-stage deals, forcing Sanofi to drop Pompe disease partnership with Maze
The Federal Trade Commission said it would seek to block Sanofi’s proposed licensing deal for Maze Therapeutics’ clinical-stage Pompe disease treatment, leading the French pharma to say it would back out of the agreement.
Sanofi already markets Nexviazyme, a successor to its own Myozyme/Lumizyme, and the US regulator said Monday that the up to $755 million proposed deal “would eliminate a nascent competitor poised to challenge Sanofi’s monopoly in the Pompe disease therapy market.” The agency authorized a lawsuit in federal court, it said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.